EUVIMEDObjevte EUVIMED
Open access

Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I‐MIBG in patients with relapsed/refractory neuroblastoma

Vandana Batra, Ajami Gikandi iD, Bruce Pawel, Daniel Martinez, M Meaghan Granger, Araz Marachelian iD, Julie R Park, John M Maris iD, Kieuhoa T Vo iD, Katherine K Matthay iD, Steven G DuBois iD

Pediatric Blood & Cancer · 2024

DOI: 10.1002/pbc.30743 ↗

At a glance

Journal article in Pediatric Blood & Cancer, 2024. Written by Vandana Batra and 10 co-authors. Institution: Children's Hospital of Philadelphia and Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Major MEDLINE topics: 3-Iodobenzylguanidine, Neuroblastoma. Cited 4 times so far (Crossref); 19 references. The full text is freely available in PubMed Central. Funded by: NCI NIH HHS, NIH HHS, National Institutes of Health.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Prior studies suggest that norepinephrine transporter (NET) and vesicular monoamine transporter 2 (VMAT2) mediate meta‐iodobenzylguanidine (MIBG) uptake and retention in neuroblastoma tumors. We evaluated the relationship between NET and VMAT2 tumor expression and clinical response to 131 I‐MIBG therapy in patients with neuroblastoma.

Methods

Immunohistochemistry (IHC) was used to evaluate NET and VMAT2 protein expression levels on archival tumor samples (obtained at diagnosis or relapse) from patients with relapsed or refractory neuroblastoma treated with 131 I‐MIBG. A composite protein expression H ‐score was determined by multiplying a semi‐quantitative intensity value (0–3+) by the percentage of tumor cells expressing the protein.

Results

Tumor samples and clinical data were available for 106 patients, of whom 28.3% had partial response (PR) or higher. NET H ‐score was not significantly associated with response (≥PR), though the percentage of tumor cells expressing NET was lower among responders (median 80% for ≥PR vs. 90% for

Subjects

MeSH terms (MEDLINE)

3-IodobenzylguanidineNeuroblastomaHumansNorepinephrine Plasma Membrane Transport ProteinsVesicular Monoamine Transport ProteinsRadiopharmaceuticalsN-Myc Proto-Oncogene ProteinNeoplasm Recurrence, LocalChronic Disease

Author keywords

131I-MIBGbiomarkerneuroblastomanorepinephrine transportervesicular monoamine transporter 2

Substances

3-IodobenzylguanidineNorepinephrine Plasma Membrane Transport ProteinsVesicular Monoamine Transport ProteinsRadiopharmaceuticalsN-Myc Proto-Oncogene Protein

Authors and institutions

  • Children's Hospital of Philadelphia and Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Pathology, Children's Hospital Los Angeles and USC Keck School of Medicine, Los Angeles, California, USA.
  • Department of Pediatrics, Cook Children's Hospital, Fort Worth, Texas, USA.
  • Department of Pediatrics, Children's Hospital Los Angeles and USC Keck School of Medicine, Los Angeles, California, USA.
  • Department of Pediatrics, Seattle Children's Hospital and University of Washington School of Medicine, Seattle, Washington, USA.

ORCID profiles: Ajami Gikandi, Araz Marachelian, John M Maris, Kieuhoa T Vo, Katherine K Matthay, Steven G DuBois

Funding

  • NCI NIH HHS
  • NIH HHS
  • National Institutes of Health

Cite

APA

Batra, V., Gikandi, A., Pawel, B., Martinez, D., Granger, M. M., Marachelian, A., Park, J. R., Maris, J. M., Vo, K. T., Matthay, K. K., & DuBois, S. G. (2024). Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I‐MIBG in patients with relapsed/refractory neuroblastoma. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30743

Vancouver

Batra V, Gikandi A, Pawel B, Martinez D, Granger MM, Marachelian A, et al. Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I‐MIBG in patients with relapsed/refractory neuroblastoma. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30743

BibTeX
@article{Batra2024,
  author = {Batra, Vandana and Gikandi, Ajami and Pawel, Bruce and Martinez, Daniel and Granger, M Meaghan and Marachelian, Araz and Park, Julie R and Maris, John M and Vo, Kieuhoa T and Matthay, Katherine K and DuBois, Steven G},
  title = {Norepinephrine transporter and vesicular monoamine transporter 2 tumor expression as a predictor of response to 131 I‐MIBG in patients with relapsed/refractory neuroblastoma},
  journal = {Pediatric Blood & Cancer},
  year = {2024},
  doi = {10.1002/pbc.30743}
}
Start for free →